US momentum leaders — October 2026

Bumble's shares trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, leaving little room above the 23 October 2026 close of $5.96.…

AudioEye is now profitable, but 7% sales growth and its executive chairman's roughly $2.4 million of stock sales make the shares more likely to…

Silence Therapeutics trades as a pending $20-per-ADS cash takeover by Merck KGaA, which caps the upside; the scheme vote, UK court sanction and…

Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares near the offer, so they are more likely to lag the S&P 500 than lead…

Surgery Partners' shares, at $23.17 on 5 November 2026, trade just under HealthSpan Partners' $23.50 cash takeover price, leaving little room to…

Genmab's own cancer drugs are becoming a second engine beside its DARZALEX royalty, and the 5 November 2026 report left 2026 guidance intact. Full…

DMC Global shares look more likely to lag the S&P 500 than lead it despite a real cost-cut recovery; a softer fourth-quarter guide and the open…

Grid Dynamics' AI work is lifting the IT-services firm back toward double-digit growth at margins near 20%; the fourth-quarter report, expected…

ADT Inc. trades as a pending $10.00-per-share cash takeover by Thrive Holdings, leaving the shares little room above the $9.86 close unless a…

Myriad Genetics shares look more likely to lag the S&P 500 after the $210 million prenatal sale to Labcorp lifted them above most analyst targets;…

SkyAI's shares trade just under its $3.00 cash tender offer for up to 95% of the stock, leaving little room to beat the market; the offer's 12…

MediaAlpha's case stays modestly positive: EverQuote's 2 November 2026 results confirm insurers are still raising ad spending, while White…

FIGS, the healthcare-apparel maker, beat third-quarter estimates and raised its 2026 outlook on 5 November 2026, showing demand running ahead of…

Teladoc Health beat Q3 2026 revenue and earnings estimates, but BetterHelp paying users fell to 0.336 million and Q4 BetterHelp revenue is guided…

Black Rock Coffee Bar's new stores still lift revenue about 25% a year, but same-store sales are slowing and the shares rose 55.4% in three months…

Glaukos's iDose TR glaucoma implant and Epioxa keratoconus therapy lifted third-quarter 2026 sales 58% to $211.0 million and back a $1 billion…

Pacira BioSciences now trades as a pending takeover. Viatris's $36.50-per-share cash tender offer caps the upside just above the $36.39 close on…

Range Resources trades as a stand-in for EQT stock under EQT's all-stock offer of 0.987 EQT shares per share. With the premium priced in, EQT's…